Your session is about to expire
← Back to Search
Dietary Supplement
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD
N/A
Waitlist Available
Led By Brendan Lee, M.D., PhD
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Summary
This trial will study the effects of a dietary supplement on cognition in patients with a rare genetic disorder.
Eligible Conditions
- Urea Cycle Disorder
- Alpha-1 Antitrypsin Deficiency
- Argininosuccinate Lyase Deficiency
- Urea Cycle Deficiencies
- Argininosuccinic Aciduria
- Urea Cycle Disorders
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Conners Continuous Performance Test - 3rd Edition Conners Continuous Performance Test - 3rd Edition
Delis-Kaplan Executive Function System - Tower subtest
Grip Strength
+4 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: Neo-ASAActive Control1 Intervention
During this arm the participant will receive a lozenge with nitric oxide as a dietary supplement twice daily.
Group II: PlaceboPlacebo Group1 Intervention
During this arm the participant will receive a lozenge which will not contain nitric oxide as a dietary supplement twice daily.
Find a Location
Who is running the clinical trial?
Baylor College of MedicineLead Sponsor
1,028 Previous Clinical Trials
6,030,146 Total Patients Enrolled
Rare Diseases Clinical Research NetworkNETWORK
68 Previous Clinical Trials
19,193 Total Patients Enrolled
Neogenis LaboratoriesOTHER
5 Previous Clinical Trials
178 Total Patients Enrolled
Brendan Lee, M.D., PhDPrincipal InvestigatorBaylor College of Medicine
1 Previous Clinical Trials
79 Total Patients Enrolled
Sandesh C Nagamani, M.D.Principal InvestigatorBaylor College of Medicine